Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study
Open accessThe DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index; 12 of the 20 sources its claims cite were checked for support.
Abstract
Referenced in the proposal as support for focal parenchymal atrophy in prediagnostic CT.
Overview
CoChat Summary
TL;DR
This retrospective case-control study found focal parenchymal atrophy (FPA) on pre-diagnostic CT in 26/76 (34.2%) patients who later had PDAC, versus 3/76 (3.9%) matched controls, suggesting FPA may be an early imaging sign of pancreatic cancer. The paper also reports that FPA often appeared before main pancreatic duct (MPD) changes and was less common in pancreatic head tumors than in body/tail tumors.
Key findings
- FPA was seen on pre-diagnostic CT in 26/76 (34.2%) PDAC patients and 3/76 (3.9%) controls without PDAC; the difference was significant (p < 0.001).
- By timing before PDAC diagnosis, FPA was detected in 14/44 (31.8%) patients at 6 months–1 year, 14/51 (27.5%) at 1–2 years, and 9/41 (22.0%) at 2–3 years before diagnosis.
- MPD cut-off/dilatation increased as diagnosis approached: 12/44 (27.3%) at 6 months–1 year, 7/51 (13.7%) at 1–2 years, and 1/41 (2.4%) at 2–3 years; the trend was significant (p < 0.0001), while FPA was described as appearing earlier than MPD changes.
- FPA was less frequent in pancreatic head PDAC: 3/27 (11.1%) in the head versus 14/30 (46.7%) in the body and 9/19 (47.4%) in the tail (p = 0.0045).
Methods
- Retrospective case-control study approved by the Tohoku University ethics committee; informed consent was waived.
- Cases: 76 patients with histopathologically confirmed PDAC who had CT 6 months to 3 years before diagnosis; controls: 76 sex- and age-matched patients without PDAC who had CT at least 5 years apart.
- Two blinded reviewers independently assessed CTs for pancreatic masses, MPD cut-off/dilatation (≥3 mm upstream), FPA, and cysts; comparisons used Wilcoxon rank-sum and Fisher’s exact tests.
Limitations
- The paper states several limitations: retrospective design, limited number of patients, varying CT intervals, varied scanning protocols, and varying observation periods.
- The authors note they could not exclude that some controls might later develop PDAC, and that unenhanced CT may have missed some MPD dilatation or cysts.
- Evident from the text: CT timing was inconsistent and some scans came from other institutions, which could affect comparability of imaging assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
7 Valid · 0 Not valid · 3 Not checked · 29 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Focal parenchymal atrophy (FPA) of the pancreas has been reported as a characteristic imaging finding of early PDAC.”
- Also stated in: § 1. Introduction · boosted
“Recently, several studies have shown that focal parenchymal atrophy (FPA) of the pancreas is a characteristic imaging finding revealed on CT performed in patients with early stage PDAC, including those with stage 0 PDAC [13,14,15].”
§ Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study > Abstract
What the sources say
- Supportedcites [13] Miura, 2020, Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct, Tohoku J. Exp. Med. source
The Results report that focal parenchymal atrophy with fat replacement was detected on CT more often in early pancreatic cancer cases than in benign cases (7/10 versus 1/10). The Discussion identifies these findings as potentially useful imaging clues, supporting the claim. The study examined patients with localized main pancreatic duct strictures. (LLM, conf=0.89)
- Supportedcites [14] Yamao, K., Takenaka, M., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Omoto, S., Kamata, K., Minaga, K., and Matsumoto, I. (2020). Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. Diagnostics, 10. source
The Results (§3.3) report that partial pancreatic parenchymal atrophy was significantly more frequent on CT in patients with small pancreatic cancer than in patients with benign duct stenosis. The Discussion (§4) also describes local parenchymal atrophy as suggestive of pancreatic cancer, supporting its characterization as an imaging finding of early disease. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [15] Nakahodo, 2020, Focal Parenchymal Atrophy of Pancreas: An Important Sign of Underlying High-Grade Pancreatic Intraepithelial Neoplasia Without Invasive Carcinoma, i.e., Carcinoma in Situ, Pancreatology source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Pathological examination of the resected pancreatic tissue has revealed that FPA is associated with the loss of acinar cells and the subsequent replacement by fat or fibrosis [13,14,15].”
§ Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study > 4. Discussion
What the sources say
- Partly supportedcites [13] Miura, 2020, Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct, Tohoku J. Exp. Med. sourceExperimental — accuracy not yet measured
The section on focal parenchymal atrophy and fat replacement reports that pathological examination of resected tissue found parenchymal atrophy, fat replacement, and fibrosis in malignant cases. It does not identify loss of acinar cells or establish that fat or fibrosis subsequently replaced those cells. (LLM, conf=0.84)
- Partly supportedcites [14] Yamao, K., Takenaka, M., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Omoto, S., Kamata, K., Minaga, K., and Matsumoto, I. (2020). Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. Diagnostics, 10. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says loss of acinar cells is replaced by fibrotic changes and cites pathological assessments showing fatty changes alongside fibrosis and atrophy. It does not state that fat replaces the lost acinar cells; its own study assessed CT findings rather than establishing that sequence through examination of resected tissue. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [15] Nakahodo, 2020, Focal Parenchymal Atrophy of Pancreas: An Important Sign of Underlying High-Grade Pancreatic Intraepithelial Neoplasia Without Invasive Carcinoma, i.e., Carcinoma in Situ, Pancreatology source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“FPA is sometimes detected in healthy subjects and those with benign diseases, ranging from 7.8% to 15.8% [13,14,15].”
§ Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study > 4. Discussion
What the sources say
- Partly supportedcites [13] Miura, 2020, Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct, Tohoku J. Exp. Med. sourceExperimental — accuracy not yet measured
The imaging-findings section reports focal parenchymal atrophy with fat replacement in 1 of 10 patients (10%) with benign main pancreatic duct strictures, which supports occasional detection in a benign group. It does not study healthy subjects or establish the stated 7.8%–15.8% range; page numbers are unavailable in our copy. (LLM, conf=0.85)
- Partly supportedcites [14] Yamao, K., Takenaka, M., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Omoto, S., Kamata, K., Minaga, K., and Matsumoto, I. (2020). Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. Diagnostics, 10. sourceExperimental — accuracy not yet measured
The Results (§3.3; page not provided) report partial pancreatic parenchymal atrophy in 7.1% of patients with benign main pancreatic duct stenosis, supporting its occasional presence in a benign condition. The paper does not report findings in healthy subjects or the claimed 7.8%–15.8% range. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [15] Nakahodo, 2020, Focal Parenchymal Atrophy of Pancreas: An Important Sign of Underlying High-Grade Pancreatic Intraepithelial Neoplasia Without Invasive Carcinoma, i.e., Carcinoma in Situ, Pancreatology source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequency of MPD cut-off/dilatation increased in a time-dependent manner as approaching the diagnosis (p < 0.0001).”
§ Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study > 3. Results > 3.2. FPA Was Frequently Observed on Pre-Diagnostic CT
plainstates an associationn = 76 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, FPA was more frequently observed in patients with PDAC (26/76; 34.2%) on pre-diagnostic CT than that in controls (3/76; 3.9%) (p < 0.001).”
- Also stated in: § 3.4. FPA Was More Frequently Observed in Patients with PDAC Than Controls without PDAC on Pre-Diagnostic CT · plain
“FPA was more frequently observed on pre-diagnostic CT in patients with PDAC than controls without PDAC (p < 0.001).”
§ Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study > Abstract
plainstates an associationn = 76- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § 3.4. FPA Was More Frequently Observed in Patients with PDAC Than Controls without PDAC on Pre-Diagnostic CT · plain
11 more claims
Create a free account to see all 39 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 17
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The chief reasons for CT examinations in the 76 controls were follow-up of the following diseases: hepatocellular carcinoma (n = 24), gastric cancer (n = 19), gallbladder stone (n = 6), adenomyomatosis of the gallbladder (n = 6), biliary cancer (n = 6), gallbladder polyp (n = 5), chronic hepatitis (n = 3), retroperitoneal tumor (n = 2), hypergastrinemia (n = 1), colon cancer (n = 1), and dilatation of bile duct (n = 1).”
§ Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study > 2. Materials and Methods > 2.2. Subjects
Reported 76 · recomputed 74
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482
Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society
Egawa, S., Toma, H., Ohigashi, H., Okusaka, T., Nakao, A., Hatori, T., Maguchi, H., Yanagisawa, A., & Tanaka, M. (2012) · Pancreas · doi:10.1097/mpa.0b013e318258055c · Cited by 434
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.10232 · Cited by 419
Canto, M. I., Almario, J. A., Schulick, R. D., Yeo, C. J., Klein, A., Blackford, A., Shin, E. J., Sanyal, A., Yenokyan, G., Lennon, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.035 · Cited by 414 · cited 1×
“It is reasonable to assume that further examinations for PDAC, including magnetic resonance cholangiopancreatography, endoscopic ultrasonography, and occasionally endoscopic retrograde cholangiopancreatography, should be performed if FPA is first detected in subjects at a high risk of PDAC, including subjects from fam…”
BackgroundImaging diagnosis of pancreatic cancer: A state-of-the-art review
Lee, E. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7864 · Cited by 401
(2006) · PubMed · Cited by 347
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review
Aslanian, H. R., Lee, J. H., & Canto, M. I. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.088 · Cited by 317 · cited 2×
“[27], scre ning in those who are at hig risk of PDAC, including those with newonset diabetes, provides diagnostic opportunities [28,29].”
BackgroundMulticenter study of early pancreatic cancer in Japan
Kanno, A., Masamune, A., Hanada, K., Maguchi, H., Shimizu, Y., Ueki, T., Hasebe, O., Ohtsuka, T., Nakamura, M., Takenaka, M., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2017.11.007 · Cited by 291 · cited 3×
“In a multi-center study conducted in Japan, PDAC was detected due to abnormalities during the follow-up/workup of other diseases in approximately 50% of patients with early stage PDAC [16].”
BackgroundSelf-citationBlackford, A. L., Canto, M. I., Klein, A. P., Hruban, R. H., & Goggins, M. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa004 · Cited by 270
Gangi, S., Fletcher, J. G., Nathan, M. A., Christensen, J. A., Harmsen, W. S., Crownhart, B. S., & Chari, S. T. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.4.1820897 · Cited by 249
Pelaez-Luna, M., Takahashi, N., Fletcher, J. G., & Chari, S. T. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01480.x · Cited by 180
Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review
Elbanna, K. Y., Jang, H.-J., & Kim, T. K. (2020) · Insights into Imaging · doi:10.1186/s13244-020-00861-y · Cited by 162 · cited 3×
“his is in contrast to other imaging findi s, such as MPD changes, cysts, and tumors, which usually require enhanced CT [11].”
BackgroundResultInfluentialArtificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Cancer‐associated adipocytes promote pancreatic cancer progression through SAA1 expression
Takehara, M., Sato, Y., Kimura, T., Noda, K., Miyamoto, H., Fujino, Y., Miyoshi, J., Nakamura, F., Wada, H., Bando, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14527 · Cited by 125
Defining the molecular pathology of pancreatic body and tail adenocarcinoma
Initiative, A. P. C. G., Dreyer, S. B., Jamieson, N. B., Upstill-Goddard, R., Bailey, P. J., McKay, C. J., Biankin, A. V., & Chang, D. K. (2018) · British Journal of Surgery · doi:10.1002/bjs.10772 · Cited by 122
Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans
Takahashi, M., Hori, M., Ishigamori, R., Mutoh, M., Imai, T., & Nakagama, H. (2018) · Cancer Science · doi:10.1111/cas.13766 · Cited by 120
Indicative findings of pancreatic cancer in prediagnostic CT
Ahn, S. S., Kim, M.-J., Choi, J.-Y., Hong, H.-S., Chung, Y. E., & Lim, J. S. (2009) · European Radiology · doi:10.1007/s00330-009-1422-6 · Cited by 105
Matsuda, Y., Furukawa, T., Yachida, S., Nishimura, M., Seki, A., Nonaka, K., Aida, J., Takubo, K., Ishiwata, T., Kimura, W., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000786 · Cited by 89 · cited 1×
“[25] reported that carcinoma in situ was observed more frequently in the pancreatic body and tail than in the pancreatic head in autopsied cases, suggesting that the mechanism of carcinogenesis differs depending on the tumor location in the pancreas.”
BackgroundNakahodo, J., Kikuyama, M., Nojiri, S., Chiba, K., Yoshimoto, K., Kamisawa, T., Horiguchi, S.-I., & Honda, G. (2020) · Pancreatology · doi:10.1016/j.pan.2020.09.020 · Cited by 87 · cited 3×
“[15] reported that among the 46 patients suspected of early stage PDAC, FPA was observed in 15/27 (55.”
BackgroundInfluentialToshima, F., Watanabe, R., Inoue, D., Yoneda, N., Yamamoto, T., Sasahira, N., Sasaki, T., Matsuyama, M., Minehiro, K., Tateishi, U., et al. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26014 · Cited by 81
Singh, D. P., Sheedy, S., Goenka, A. H., Wells, M., Lee, N. J., Barlow, J., Sharma, A., Kandlakunta, H., Chandra, S., Garg, S. K., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.07.410 · Cited by 62
Matsuda, Y. (2019) · Pathology International · doi:10.1111/pin.12837 · Cited by 61
Yamao, K., Takenaka, M., Ishikawa, R., Okamoto, A., Yamazaki, T., Nakai, A., Omoto, S., Kamata, K., Minaga, K., Matsumoto, I., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10070445 · Cited by 58
Pancreas Size and Volume on Computed Tomography in Normal Adults
Syed, A.-B., Mahal, R. S., Schumm, L. P., & Dachman, A. H. (2011) · Pancreas · doi:10.1097/mpa.0b013e318237457f · Cited by 43
Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma
Desai, V., Patel, K., Sheth, R., Barlass, U., Chan, Y.-M., Sclamberg, J., & Bishehsari, F. (2020) · Visceral Medicine · doi:10.1159/000507457 · Cited by 40
Clinicopathological Characteristics of Young Patients With Pancreatic Cancer
Eguchi, H., Yamaue, H., Unno, M., Mizuma, M., Hamada, S., Igarashi, H., Kuroki, T., Satoi, S., Shimizu, Y., Tani, M., et al. (2016) · Pancreas · doi:10.1097/mpa.0000000000000636 · Cited by 38
Self-citationAsymptomatic pancreatic cancer: does incidental detection impact long-term outcomes?
Takeda, Y., Saiura, A., Takahashi, Y., Inoue, Y., Ishizawa, T., Mise, Y., Matsumura, M., Ichida, H., Matsuki, R., Tanaka, M., et al. (2017) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-017-3421-2 · Cited by 27 · cited 1×
“Patients with incidentally detected PDAC during examination for other diseases have a better prognosis than those with PDAC diagnosed on symptom presentation [29,30].”
BackgroundSimultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma
Hamada, S., Shimosegawa, T., Taguchi, K., Nabeshima, T., Yamamoto, M. P., & Masamune, A. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00228.2017 · Cited by 24
Self-citationMiura, S., Kume, K., Kikuta, K., Hamada, S., Takikawa, T., Yoshida, N., Hongo, S., Tanaka, Y., Matsumoto, R., Sano, T., et al. (2020) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.252.63 · Cited by 22 · cited 2×
“[13] reported that FPA was observed in 7/10 (70%) patients with early stage PDAC but only in 1/10 (10%) patients with benign MPD stricture/dilatation.”
BackgroundSelf-citationNew-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer
Takikawa, T., Kikuta, K., Kume, K., Hamada, S., Miura, S., Yoshida, N., Hongo, S., Tanaka, Y., Matsumoto, R., Sano, T., et al. (2020) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.252.353 · Cited by 14
Self-citationVasen, H. F. A., Boekestijn, B., Ibrahim, I. S., Inderson, A., Bonsing, B. A., de Vos tot Nederveen Cappel, W. H., Feshtali, S., & Wasser, M. N. (2019) · HPB · doi:10.1016/j.hpb.2019.02.013 · Cited by 12
Masamune, A., Hamada, S., Yoshida, N., Nabeshima, T., & Shimosegawa, T. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5051-2 · Cited by 8
Self-citation
Research works printed but not linked: 1
- Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). American Joint Committee on Cancer. AJCC Cancer Staging Manual, Springer. [8th ed.].
Cited by
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 512
Clinical features and prognostic impact of asymptomatic pancreatic cancer
Takikawa, T., Kikuta, K., Hamada, S., Kume, K., Miura, S., Yoshida, N., Tanaka, Y., Matsumoto, R., Ikeda, M., Kataoka, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08083-6 · Cited by 56
Self-citationFatty Pancreas and Pancreatic Cancer: An Overlooked Association?
(2022) · doi:10.3390/jcm11030763 · Cited by 28
The role of biomarkers in the early detection of pancreatic cancer
Goggins, M. (2024) · Familial Cancer · doi:10.1007/s10689-024-00381-4 · Cited by 35
Gonda, M., Masuda, A., Kobayashi, T., Iemoto, T., Kakuyama, S., Ezaki, T., Ikegawa, T., Hirata, Y., Tsumura, H., Ogisu, K., et al. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12557 · Cited by 21
Metadata
- Authors
- Miura, S., Takikawa, T., Kikuta, K., Hamada, S., Kume, K., Yoshida, N., Tanaka, Y., Matsumoto, R., Ikeda, M., Kataoka, F., Sasaki, A., Hatta, W., Inoue, J., & Masamune, A.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Masamune, Atsushi
- ORCID
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2021-09-17
- Volume
- 11
- Issue
- 9
- Pages
- 1693
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC8471718
- OpenAlex
- W3201634989
- Semantic Scholar
- 722285b4281143c33df1636df232f280e06018bf
- Cited by
- 38
- References
- 39
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 8 · 2023: 5 · 2022: 5
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (21K15915)
- KUROKAWA CANCER RESEARCH FOUNDATION (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pancreatic ductal adenocarcinoma, pancreatic cancer, early diagnosis, tumor location, pancreatic head, pancreatic body and tail
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.